Glaukos is delighted to announce a major milestone revealing that 3 million iStents have been sold globally since the product first received approval from the FDA in 2012.
Today iStent is the global market leader in the MIGs category with Trabecular Micro-bypass (TMB) procedures being routinely performed on glaucoma patients undergoing cataract surgery.
Glaukos continues to expand its market leading position. The company now operates direct sales in 17 countries and employs more than 300 commercial staff worldwide.
The iStent milestone follows strong financial performance with Glaukos reporting annual 2025 sales exceeding $500 million.
FURTHER INFORMATION:
Glaukos
W: www.glaukos.com/en-uk/
